Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial.
Preliminary results of a multicenter, randomized study on the effect of natural interferon beta (n-INFN-beta) in relapsing-remitting MS are reported. Sixty patients received either no treatment or n-IFN-beta (9 MIU three times a week, subcutaneously). After 6 months, the n-IFN-beta-treated group showed a 58% median reduction in the number of active lesions detected on monthly magnetic resonance imaging scans as well as a 38% reduction in the exacerbation rate as compared with the control group. Side-effects were mild and self-limiting. The study continues according to the protocol.
Fernández
O
O
Department of Neurology, Hospital Carlos Haya, Malaga, Spain.
Antiquëdad
A
A
Arbizu
T
T
Capdevíla
A
A
de Castro
P
P
Correa de Sa
J C
JC
García-Merino
J A
JA
Izquierdo
G
G
Magalhaes
A
A
Montalbán
X
X
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000293:Adolescent; D000328:Adult; D006801:Humans; D016899:Interferon-beta / Q000008:administration & dosage*; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000628:therapy*; D012008:Recurrence
D000276:Adjuvants, Immunologic; D016899:Interferon-beta